Table 5. Change in EQ-5D-3L utility score after 2 years of follow-up according to use of β2-microglobulin apheresis column.

	Mean change (95% CI)	Difference (95% CI)	P
Crude analysis
β2-MG apheresis column	0.01 (−0.04 to 0.06)	0.05 (−0.01 to 0.11)	0.088
No β2-MG apheresis column	−0.04 (−0.07 to −0.01)	Reference
Multivariable analysis (Model 1)
β2-MG apheresis column	0.01 (−0.01 to 0.12)	0.07 (0.00 to 0.14)	0.062
No β2-MG apheresis column	−0.06 (−0.16 to 0.05)	Reference
Multivariable analysis (Model 2)
β2-MG apheresis column	0.09 (−0.07 to 0.26)	0.07 (0.00 to 0.14)	0.064
No β2-MG apheresis column	0.02 (−0.13 to 0.18)	Reference
Multivariable analysis (Model 3)
β2-MG apheresis column	−0.05 (−0.19 to 0.08)	0.08 (0.01 to 0.15)	0.017
No β2-MG apheresis column	−0.14 (−0.26 to −0.01)	Reference

Model 1: Adjusted for age, age at hemodialysis onset, sex, diabetic nephropathy, dialysis vintage, history of myocardial infarction, ischemic stroke, intracerebral hemorrhage or amputation, predialysis body mass index, Kt/V, geriatric nutritional risk index, hemoglobin, C-reactive protein, use of benzodiazepine agents.

Model 2: Adjusted for covariates in Model 1 plus new-onset myocardial infarction, ischemic stroke, intracerebral hemorrhage or amputation during follow-up.

Model 3: Adjusted for all factors in Model 2 except for Kt/V and C-reactive protein.

Abbreviations: β2-MG, β2-microglobulin; CI, confidence interval; EQ-5D-3L, EuroQol 5-Dimensions 3-Levels Questionnaire.